focus -WSS

focus

author：hotspot 2025-09-27 13:03:18 - browse：86

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Cybersecurity threat forces Lurie Children's to take systems offline

focus

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

Some dementia cases could be undiagnosed liver disease

Study suggests Covid rebound is far more common with Paxlovid than without

How state and local governments are sidelining science

A letter from the executive editor: STAT UnitedHealth investigation

Ohio still needs to do more to protect the right to abortion

hotspot

focus

knowledge

Affirmative action in medical school literally saved lives

Congressmen charge Covid hearing ‘could have been an email’

Sports medicine is finally prioritizing gender equality

A letter from the executive editor: STAT UnitedHealth investigation

State Dept. review finds Biden bears some blame for Afghanistan failures

Medical school prerequisites are outdated

Hepatitis C has a cure — but many Americans still lack access to it

Some dementia cases could be undiagnosed liver disease

What does generative AI mean for health care? We asked experts

Medicare’s new pay boost for primary care is angering specialists

explore

Experimental asthma app from Apple and Anthem shows promise

FDA reorg will put new emphasis on investigations, sources say

Even great ERs can’t make up for American health disparities

Weight loss drugs should be covered by insurers, AMA says

Experimental asthma app from Apple and Anthem shows promise

FDA drug safety: Singulair case shows systemic surveillance flaws

explore

focus

focus

entertainment